[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2016[J]. CA Cancer J Clin,2016,66(1):7-30. [2] Desantis CE, Fedewa SA, Goding Sauer A, et al.Breast cancer statistics, 2015: Convergence of incidence rates between black and white women[J]. CA Cancer J Clin,2016,66(1):31-42. [3] Fan L, Strasser-Weippl K, Li JJ, et al.Breast cancer in China[J]. Lancet Oncol,2014,15(7):e279-e289. [4] Shi J, Liang D, Jin J, et al.Female breast cancer burden was increasing during the 40 years in Hebei Province, China: a population-based study[J]. Arch Gynecol Obstet,2016,294(5):1-9. [5] Mundy GR.Metastasis to bone: causes, consequences and therapeutic opportunities[J]. Nat Rev Cancer,2002,2(8):584-593. [6] Harries M, Taylor A, Holmberg L, et al.Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients[J]. Cancer Epidemiol,2014,38(4):427-434. [7] Svendsen ML, Gammelager H, Sværke C, et al.Hospital visits among women with skeletal-related events se-condary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark[J]. Clin Epidemiol,2013,5:97-103. [8] Stewart LA, Clarke M, Rovers M, et al.Preferred repor-ting items for a systematic review and Meta-analysis of individual participant data: The PRISMA-IPD statement[J]. JAMA,2015,313(16):1657-1665. [9] Lo KL, Mertz D, Loeb M.Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments[J]. BMC Med Res Methodol,2014,14(1):45. [10] Dibekoglu C, Turanli S, Karaman N, et al.Bone fracture in breast cancer patients with isolated bone metastasis[J]. Chirurgia,2015,110(1):43-48. [11] Yamashiro H, Takada M, Nakatani E, et al.Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan[J].Int J Clin Oncol,2014,19(5):852-862. [12] Kuchuk I, Hutton B, Moretto P, et al.Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre[J]. J Bone Oncol,2013,2(4):137-144. [13] 丁晓燕, 樊英, 马飞, 等. 绝经后乳腺癌骨转移病人骨相关事件及预后分析[J]. 肿瘤防治研究,2012,39(6):627-631. [14] Trinkaus M, Simmons C, Myers J, et al.Skeletal-related events (SRE) in breast cancer patients with bone metastases treated in the nontrial setting[J]. Support Care Cancer,2010,18(2):197-203. [15] Domchek SM, Younger J, Finkelstein DM, et al.Predictors of skeletal complications in patients with metastatic breast carcinoma[J]. Cancer,2000,89(2):363-368. [16] Carter JA, Ji X, Botteman MF.Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases[J]. Expert Rev Pharmacoecon Outcomes Res,2013,13(4):483-496. [17] Kaminski M, Rosen L, Gordon D, et al.Zoledronic acid versus pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications[J]. J Clin Oncol,2004,22(14):S857. [18] Ferreira AR, Alho I, Shan N, et al.N-telopeptide of type Ⅰ collagen long-term dynamics in breast cancer patients with bone metastases: clinical outcomes and influence of extraskeletal metastases[J]. Oncologist,2016,21(12):1418-1426. [19] Brown JE, Cook RJ, Lipton A, et al.Prognostic factors for skeletal complications from metastatic bone disease in breast cancer[J]. Breast Cancer Res Treat,2010,123(3):767-779. [20] Amadori D, Aglietta M, Alessi B, et al.Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer(ZOOM): a phase 3, open-label, randomised, non-inferiority trial[J]. Lancet Oncol,2013,14(7):663-670. [21] Amir E, Freedman O, Carlsson L, et al.Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer[J]. J Clin Oncol,2013,36(5):436-442. [22] Mathew A, Brufsky A.Bisphosphonates in breast cancer[J]. Int J Cancer,2015,137(4):753-764. [23] Mathew A, Brufsky A.Breast cancer: zoledronic acid--more than just a bone drug[J]. Nat Rev Clin Oncol,2014,11(10):564-565. |